Lilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin
Rhea-AI Summary
Eli Lilly (NYSE: LLY) announced a $3 billion expansion of its Kenosha County, Wisconsin manufacturing facility. The expansion will enhance the company's injectable product manufacturing network to meet growing demand for diabetes, obesity, and future pipeline medicines. The project will add 750 highly skilled jobs to the current 100-plus workforce.
Construction is set to begin in 2025. Combined with the initial acquisition, land purchases, and warehouse additions, Lilly's total planned investment in Wisconsin reaches $4 billion. The facility will utilize advanced automation, including guided vehicles, robotics, and digital automation for medicine production. The project will also create over 2,000 construction jobs during the expansion phase.
Positive
- Major $3 billion investment expanding manufacturing capacity
- Addition of 750 new high-skilled jobs
- Enhanced production capabilities for high-demand products (diabetes and obesity medicines)
- Implementation of advanced automation technology to improve efficiency
- Total Wisconsin investment reaching $4 billion showing strong commitment to growth
Negative
- Significant capital expenditure requiring substantial financial commitment
- Extended timeline for return on investment with construction starting in 2025
News Market Reaction – LLY
In the trading session that priced this news, LLY declined 0.51%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The investment will benefit millions of patients worldwide, boosting the production of the company's medicines, including those for diabetes and obesity
The company plans to start construction on the expansion next year. This represents another step in Lilly's historic manufacturing expansion agenda to help more people who depend on its medicines. Since 2020, Lilly has committed more than
"Today's announcement represents our single largest
The acquisition, expansion, and additional purchases of land and the adjacent warehouse bring Lilly's total planned investment in
Lilly will use advanced automation, including guided vehicles, robotics and production equipment, to accelerate medicine production. From data management to operations, digital automation will be embedded throughout the site to accelerate processes and increase accuracy, allowing employees to focus on making safe, high-quality medicines.
New highly skilled jobs at the site will include operators, technicians, engineers and scientists – in addition to more than 2,000 construction jobs during the expansion project's construction.
"
Lilly aims to advance innovation in pharmaceutical manufacturing by fostering partnerships with local higher education institutions and supporting various community initiatives in
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. C-LLY
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) including about planned capital investments in new manufacturing capacity, production of medicines, hiring and related initiatives and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in the manufacturing process, development and commercialization of pharmaceutical products any of which could impact the overall commercial success of our products, and as related to cost, completion timing, expected capacity, personnel, and other factors which could impact expected benefits of the capacity expansion and related initiatives. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Additional quotes for media use:
Refer to: | Carrie Munk; munk_carrie@lilly.com; 317-416-2393 (Media) |
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-announces-3-billion-expansion-of-its-recently-acquired-manufacturing-facility-in-wisconsin-302324087.html
SOURCE Eli Lilly and Company